Antibiotic Bootcamps for Developers: Post-Approval Economics for New Antibiotics
ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
3-6 September 2019, Boston
Collaboratively organized by GARDP, CARB-X, REPAIR Impact Fund, JPIMAR and Wellcome Trust
Moderator: Ryan Cirz
Speakers: Kevin Krause (AN2 Therapeutics, U.S. and formerly Achaogen), Craig Lichtenstein (Sana Biotechnology, U.S. and formerly Achaogen), Rolf Wagenaar (CD&E Consulting LLC, U.S.)
Q&A session: Kevin Krause (AN2 Therapeutics, U.S. and formerly Achaogen), Craig Lichtenstein (Sana Biotechnology, U.S. and formerly Achaogen), Rolf Wagenaar (CD&E Consulting LLC, U.S.), Ryan Cirz
- Introduction & background (John H. Rex & Ryan Cirz)
- Post-Marketing Commitments and Antimicrobial Susceptibility Test Development (Kevin Krause)
- Supply Chain Robustness, Inventory Build, and Quality Assurance (Craig Lichtenstein)
- Sales and Marketing (Rolf Wagenaar)
- Additional Economic Considerations (Kevin Krause)
- Questions & answers